FFA2 Activation Ameliorates 2,4-Dinitrochlorobenzene-Induced Atopic Dermatitis in Mice

Jisoo Kang¹ and Dong-Soon Im¹²,⁎

¹Laboratory of Pharmacology, Department of Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, ²Laboratory of Pharmacology, College of Pharmacy, and Department of Life Nanopharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea

Abstract
Gut microbiota produce dietary metabolites such as short-chain fatty acids, which exhibit anti-inflammatory effects. Free fatty acid receptor 2 (FFA2, formerly known as GPR43) is a specific receptor for short-chain fatty acids, such as acetate that regulates inflammatory responses. However, the therapeutic potential of FFA2 agonists for treatment of atopic dermatitis has not been investigated. We investigated the efficacy of the FFA2 agonist, 4-chloro-α-(1-methylethyl)-N-2-thiazoylylbenzeneacetanilide (4-CMTB), for treatment of atopic dermatitis induced by 2,4-dinitrochlorobenzene (DNCB). Long-term application of DNCB to the ears of mice resulted in significantly increased IgE in the serum, and induced atopic dermatitis-like skin lesions, characterized by mast cell accumulation and skin tissue hypertrophy. Treatment with 4-CMTB (10 mg/kg, i.p.) significantly suppressed DNCB-induced changes in IgE levels, ear skin hypertrophy, and mast cell accumulation. Treatment with 4-CMTB reduced DNCB-induced increases in Th2 cytokine (IL-4 and IL-13) levels in the ears, but did not alter Th1 or Th17 cytokine (IFN-γ and IL-17) levels. Furthermore, 4-CMTB blocked DNCB-induced lymph node enlargement. In conclusion, activation of FFA2 ameliorated DNCB-induced atopic dermatitis, which suggested that FFA2 is a therapeutic target for atopic dermatitis.

Key Words: Atopy, Dermatitis, Free fatty acid receptor 2, FFA2, Short chain fatty acids

INTRODUCTION
Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by intense pruritus and eczematous patches or plaques with a complex etiology (Davidson et al., 2019). Atopic dermatitis affects up to 20% of children worldwide and can significantly impair the quality of life owing to emotional distress, sleep disruption, and social awkwardness (Leung and Guttman-Yassky, 2017). Gut microbiota produce dietary metabolites such as short-chain fatty acids, which exert anti-inflammatory effects (Trompette et al., 2014). Free fatty acid receptor 2 (FFA2, formerly known as GPR43) is a specific receptor for short-chain fatty acids such as acetate, propionate, and butyrate (Brown et al., 2003; Le Poul et al., 2003; Nilsson et al., 2003). Activation of FFA2 by short-chain fatty acids regulates inflammatory responses (Ulven, 2012; Miyamoto et al., 2017; Sun et al., 2017; Tan et al., 2017). Furthermore, FFA2 knockout mice did not experience resolution of certain inflammatory responses in models of colitis, arthritis, and asthma, which indicated that FFA2 was necessary for resolution of inflammation (Maslowski et al., 2009). Lower concentrations of fecal acetate at 3 months of age correlated with an increased risk for the development of atopy in childhood (Arrieta et al., 2015). Although accumulating evidence supports the existence of a metabolite-mediated gut-skin axis of communication, the therapeutic potential of FFA2 agonists has not been investigated for treatment of atopic dermatitis (Lee et al., 2018). Therefore, we investigated the efficacy of the FFA2 agonist, 4-chloro-α-(1-methylethyl)-N-2-thiazoylylbenzeneacetanilide (4-CMTB), for treatment of atopic dermatitis induced by 2,4-dinitrochlorobenzene (DNCB) in mice (Lee et al., 2008; Smith et al., 2011).

MATERIALS AND METHODS
Materials
4-Chloro-α-(1-methylethyl)-N-2-thiazoylylbenzeneacetanilide (4-CMTB) was obtained from Innos Biotechnology Co., Ltd. (Seoul, Korea). Unless otherwise specified, reagents and solvents were purchased from Sigma-Aldrich (St. Louis, MO, USA) and used without further purification.

Open Access https://doi.org/10.4062/biomolther.2019.160
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received Sep 30, 2019 Revised Dec 3, 2019 Accepted Dec 10, 2019
Published Online Apr 13, 2020
⁎Corresponding Author
E-mail: imds@khu.ac.kr
Tel: +82-2-961-9377, Fax: +82-2-961-9580
www.biomolther.org
Tanilide was purchased from Tocris (Ellisville, MO, USA). Acetone was purchased from Junsei Chemical (Tokyo, Japan), 2,4-Dinitrochlorobenzene and olive oil were purchased from Sigma-Aldrich (St. Louis, MO, USA).

**Animals**

Seven-week-old male Balb/c mice were purchased from Daehan Biolink (DBL; Seoul, Korea) and housed in the laboratory animal facility at Pusan National University. The mice were housed three per cage in standard plastic cages with sawdust as bedding, and maintained at 22-24°C, with humidity at 60 ± 5%, with alternating light/dark cycles (lights were on between 7:00 h and 19:00 h), and provided with standard laboratory chow and water ad libitum (Huang et al., 2018). The animal experiment protocol for this study was reviewed and approved by the Pusan National University–Institutional Animal Care Committee (PNU–IACUC) (Approval Number PNU-2019-2219).

**Induction of atopic dermatitis in Balb/c mice and 4-CMTB administration**

Following a simple randomization procedure, eight-week-old male Balb/c mice were divided into the following three groups (n=5 each): a vehicle (acetone:olive oil, 3:1)-treated control group, a DNBC-treated group, and a 4-CMTB/DNCB-treated group. To induce experimental atopic dermatitis, the ventral skin was shaved, and 300 μL of 1% DNBC in acetone:olive oil (3:1) was applied to the ventral skin on day 0. Starting on day 7, the mice were challenged with 200 μL of 0.3% DNBC applied to the ears every other day for up to 48 days. From day 19 until completion of the study, the 4-CMTB/DNCB-treated group was administrated 4-CMTB (10 mg/kg body weight) via intraperitoneal injection 30 min prior to challenge. All mice were sacrificed on day 49.

**Histologic analysis and mast cell count in the skin**

After sacrifice on day 49, ear sections from mice in the different experimental groups were obtained and examined. Briefly, the ears were fixed in 10% formalin, dehydrated in 30% sucrose solution, and embedded in O.C.T. compound. Sections (8 μm) were stained with toluidine blue O (cat. T3260, Sigma-Aldrich) to visualize mast cells in the skin, and with hematoxylin and eosin (H&E) to visualize immune cell infiltration. Ear tissues from each of the five mice in each group were examined. For toluidine blue O staining, O.C.T. compound was removed from the sections, and the sections were hydrated and stained with toluidine blue O reagent for 2 min. Following staining, the sections were rinsed, dehydrated, and mounted on coverslips. Numbers of mast cells were counted from the photographs of toluidine blue O staining. For H&E staining, O.C.T. compound was removed from the sections, and the sections were hydrated and stained with hematoxylin reagent for 15 s. After rinsing with warm tap water, the sections were stained with eosin reagent for 10 s, rinsed, dehydrated, and then mounted on coverslips (Park and Im, 2019b).

**Measurement of total serum IgE levels**

Immunoglobulin E (IgE) levels in serum isolated from each group were measured using enzyme-linked immunosorbent assay (ELISA) kits. Briefly, 96-well plates (NUNC, Penfield, NY, USA) were coated with a capture antibody specific for IgE (cat. 88-50460-88, eBioscience, San Diego, CA, USA) and incubated overnight at 4°C. After washing, the plates were incubated with a blocking buffer for 2 h at room temperature. Serial dilutions of standard IgE were prepared and added to the appropriate wells to generate a calibration curve. Serum samples were added to the appropriate wells. The plates were incubated for 2 h at room temperature on a shaker, and then washed two times. A biotinylated detection antibody specific for IgE (cat. 88–50460–88, eBioscience) was added to each well, and the plates were incubated for 1 h at room temperature on a shaker. The plates were washed 4 times, and avidin-horseradish peroxidase (HRP) was added to each well. The plates were then incubated at room temperature for 30 min on a shaker. The plates were then washed 4 times and incubated with substrate solution at room temperature for 15 min. Stop solution was added, and the absorbance was measured at 450 nm.

**Reverse transcriptase polymerase chain reaction (RT-PCR)**

The expression levels of inflammatory markers in the ears of mice were measured using RT-PCR. First-strand cDNA was synthesized from total RNA isolated from ear tissue using Trizol reagent (Invitrogen, Waltham, MA, USA). Synthesized cDNA products, primers for each gene, and Promega Go-Taq DNA polymerase (Madison, WI, USA) were used for PCR analysis. Specific primers and PCR conditions were as previously described (Park and Im, 2019a). Aliquots (7 μL) were electrophoresed in 1.2% agarose gels and stained with StaySafe™ Nucleic Acid Gel Stain (Real Biotech Corporation, Taipei, Taiwan). The intensity of each PCR product was quantified by using ImageJ software (NIH, Bethesda, MD, USA) and normalized to GAPDH levels (Lee et al., 2017).

**Statistics**

Results are expressed as the mean ± standard error of the

---

**Fig. 1.** Effect of 4-CMTB on DNBC-induced atopic dermatitis in ears. (A) Macroscopic view of the ears. (B) H&E staining of ear tissue sections. (C) Ear thickness was measured from the sections (n=5). Statistically significant at ***p<0.001 level vs. the vehicle-treated mice and at ##p<0.01 level vs. the DNBC-treated mice.
mean (SEM) of 5 determinations for each animal experiment. Statistical significance was evaluated using analysis of variance (ANOVA) and Tukey's multiple comparison test. Differences were considered statistically significant for p values <0.05. Analyses were performed using GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA, USA).

RESULTS

4-CMTB suppressed DNCB-induced atopic dermatitis in the ears

To investigate the role of FFA2 in atopic dermatitis, we generated a DNCB-induced atopic dermatitis model using Balb/c mice. The mice were then treated with 4-CMTB, an FFA2 agonist, during the elicitation phase to evaluate the potential of FFA2 as a target for treatment of atopic dermatitis. Mice were treated with 0.3% DNCB on both ears every other day for 42 days to induce atopic dermatitis. 4-CMTB (10 mg/kg) was injected intraperitoneally 30 min prior to DNCB challenge starting on Day 19. Symptoms of DNCB-induced atopic dermatitis were by edema, erythema, and cracking of the skin in the exposed area (Fig. 1A). These symptoms were reduced in the group treated with 4-CMTB (Fig. 1A). In addition, H&E staining confirmed that DNCB induced increased infiltration of immune cells compared to the control group (Fig. 1B). Furthermore, the epidermis was obviously thickened upon visual inspection due to hyperkeratosis (Fig. 1B). 4-CMTB treatment significantly suppressed DNCB-induced hypertrophy of the epidermis and reduced DNCB-induced immune cell infiltration to the ears (Fig. 1B, 1C).

4-CMTB suppressed DNCB-induced infiltration of mast cells in the ears

Toluidine blue O staining was used to measure infiltration of mast cells into the dermis. Mast cells appeared as small, red-purple dots (Fig. 2A). Increased infiltration of mast cells and hypertrophy were observed in the DNCB-treated group (Fig. 2A). In contrast, fewer stained cells were observed in sections from mice treated with DNCB plus 4-CMTB than in sections from mice in the group treated only with DNCB (Fig. 2A). Mast cell number was semi-quantitatively analyzed. As shown in Fig. 2B, the number of mast cells in the dermis was higher in the DNCB group than in the control group. 4-CMTB treatment significantly reduced DNCB-induced mast cell infiltration into the dermis (Fig. 2B).

4-CMTB suppressed DNCB-induced increases in serum IgE levels

Serum IgE levels were measured to determine the immunological effects of DNCB and 4-CMTB. Hyper-production of IgE was observed in the sera of DNCB-treated mice, and 4-CMTB treatment significantly suppressed this increase (Fig. 3).

4-CMTB suppressed DNCB-induced increases in cytokine levels in the ears

Atopic dermatitis is believed to be regulated by the Th2, Th1, and Th17 responses (Koga et al., 2008; Kim et al., 2014; Muraro et al., 2016). Thus, the Th2, Th17, and Th1 responses were investigated by measuring levels of IL-4, IL-13, IL-17A, and INF-γ in the ears. Messenger RNA levels of each of the cytokines evaluated were significantly increased in ear tissue following application of DNCB (Fig. 4). 4-CMTB significantly reduced DNCB-induced increases in the Th2 cytokines IL-4 and IL-13 (Fig. 4A, 4B). In contrast, the levels of the Th17 and Th1 cytokines IL-17A and INF-γ were not significantly reduced by 4-CMTB treatment (Fig. 4C, 4D).

4-CMTB suppressed DNCB-induced atopic responses in lymph nodes

We evaluated lymph node size in drained lymph nodes. Lymph nodes are important components of the lymphatic system, and are filled with B cells and T cells. When an infection or an allergic reaction occurs, lymph nodes undergo swelling. The lymph nodes of mice treated with DNCB were swollen compared to those of the control mice, and lymph node weight was increased by 877% (Fig. 5). 4-CMTB significantly suppressed the DNCB-induced increase in lymph node weight by 43% (Fig. 5).

DISCUSSION

In this study, we showed that FFA2 activation could ameliorate the symptoms of atopic dermatitis induced by treatment of DNCB in mice, as evidenced by reduction of atopic skin.
lesions, reduced hypertrophy in the epidermis, suppression of mast cell infiltration into the dermis, suppression of serum IgE levels, reduced Th2 cytokine levels, and reduced lymph node swelling. These observations supported three main conclusions. First, FFA2 receptors functioned to regulate the immune response in the dermis. Second, an FFA2 agonist suppressed the Th2 immune response in a model of atopic immune response in the dermis. Third, systemic administration of 4-CMTB resolved atopic dermatitis in a mouse model.

Daily intake of fiber-rich foods supplies resources for the gut microbiota to produce short chain fatty acids. Activation of FFA2 by short-chain fatty acids could lead to regulation of inflammatory responses in skin diseases. A previous study showed that lower concentrations of fecal acetate at 3 months of age correlated with increased risk for development of atopy in childhood (Arrieta et al., 2015). Similarly, mice fed a high-fiber diet had increased circulating levels of short-chain fatty acids and were protected against allergic inflammation in the lung (Trompette et al., 2014).

Short-chain fatty acids as dietary metabolites produced by gut microbiota have been shown to exert anti-inflammatory effects and to regulate inflammatory responses through FFA2 (Ulven, 2012; Trompette et al., 2014; Miyamoto et al., 2017; Sun et al., 2017; Tan et al., 2017). Our study showed that FFA2 can act as an immune regulator in the gut-skin axis, and that this receptor may be a promising target for treatment of atopic dermatitis. A previous study showed that stimulation of FFA2 by short-chain fatty acids was necessary for normal resolution of several inflammatory responses in disease models of colitis, arthritis, and asthma (Maslowski et al., 2009). Our study showed that FFA2 also mediated resolution of the inflammatory skin disease atopic dermatitis in a mouse model.

Activation of FFA2 may have suppressed atopic dermatitis through several mechanisms. FFA2 in bone marrow-derived cells was shown to be largely responsible for inflammatory responses (Maslowski et al., 2009). Furthermore, FFA2 expression was reported in neutrophils and eosinophils in mice and humans (Maslowski et al., 2009; Theiler et al., 2019). Acetate induced robust calcium influx and chemotaxis in mouse and human neutrophils and eosinophils through FFA2 activation (Maslowski et al., 2009; Theiler et al., 2019). Therefore, FFA2 activation in immune cells may have contributed to reduced atopic response in our study, as evidenced by reduced IgE levels, cytokine levels, and lymph node size in mice treated with the FFA2 agonist 4-CMTB.

In this study, 4-CMTB was administrated by intraperitoneal injection instead of oral or topical administration. Because 4-CMTB was newly available commercially and has been applied only once in an in vivo experiment intraperitoneally (Schofield et al., 2018), we applied 4-CMTB by intraperitoneal injection. Intraperitoneal injection was a safe choice to see the direct pharmacodynamics effect of 4-CMTB without interruption of pharmacokinetic factors such as poor absorption. Because the purpose of the study was to evaluate FFA2 as a therapeutic target for atopic dermatitis, the administration route did not matter for it. Topical application of 4-CMTB was also considered. However, in order to get immune suppressive effect of 4-CMTB on FFA2 in immune cells as like acetate, we thought that plasma concentration of 4-CMTB should be high enough in blood and/or lymphatic circulations. Therefore, we did not apply 4-CMTB on the skin topically. Initially, 15 mg/kg of 4-CMTB was chosen, because the previous in vivo study used that dose (Schofield et al., 2018). However, the repeated administration of 15 mg/kg 4-CMTB was not tolerated by mice in this model. Therefore, we reduced the dose to 10 mg/kg and it was tolerated in mice, similar effects were observed with 5 mg/kg dose (data not shown).

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

ACKNOWLEDGMENTS

This research was supported by the Basic Science Re-
search Program of the Korean National Research Foundation funded by the Korean Ministry of Education, Science and Technology (NRF-2019R1A2C1005523).

REFERENCES

Arrieta, M. C., Stiemsma, L. T., Dimitriu, P. A., Thorson, L., Russell, S., Yurist-Doutsch, S., Kuzeljevic, B., Gold, M. J., Britton, H. M., Lefebvre, D. L., Subbarao, P., Mandhane, P., Becker, A., McNagny, K. M., Sears, M. R., Kollmann, T., Investigators, C. S., Mohn, W. W., Turvey, S. E. and Finlay, B. B. (2015) Early infancy microbial and metabolic alterations affect risk of childhood asthma. Sci. Transl. Med. 7, 307ra152.

Brown, A. J., Goldsworthy, S. M., Barnes, A. A., Elert, M. M., Tcheang, L., Daniels, D., Muir, A. I., Wigglesworth, M. J., Kinmonth, I., Fraser, N. J., Pike, N. B., Strum, J. C., Stepulski, K. M., Murdock, P. R., Holder, J. C., Marshall, F. H., Szekeres, P. G., Wilson, S., Ignar, D. M., Foord, S. M., Wise, A. and Dowell, S. J. (2003) The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J. Biol. Chem. 278, 11312-11319.

Davidson, W. F., Leung, D. Y. M., Beck, L. A., Berin, C. M., Boguniewicz, M., Busse, W. W., Chatila, T. A., Geha, R. S., Gern, J. E., Guttmann-Yassky, E., Irvine, A. D., Kim, B. S., Kong, H. H., Lack, G., Nadeau, K. C., Schwaninger, J., Simpson, A., Simpson, E. L., Spergel, J. M., Togias, A., Wahn, U., Wood, R. A., Woodfolk, J. A., Ziegler, S. F. and Plaut, M. (2019) Report from the National Institute of Allergy and Infectious Diseases workshop on “Atopic dermatitis and the atopic march: mechanisms and interventions”. J. Allergy Clin. Immunol. 143, 894-913.

Huang, J., Su, M., Lee, B. K., Kim, M. J., Jung, J. H. and Im, D. S. (2018) Suppressive effect of 4-hydroxy-2-(4-hydroxyphenethyl)isindoline-1,3-dione on ovalbumin-induced allergic asthma. Biomed. Ther. (Seoul) 26, 539-545.

Kim, J. Y., Jeong, M. S., Park, M. K., Lee, M. K. and Seo, S. J. (2014) Time-dependent progression from the acute to chronic phases in atopic dermatitis induced by epicutaneous allergen stimulation in NC/Nga mice. Exp. Dermatol. 23, 53-57.

Koga, C., Kabashima, K., Shiraishi, N., Kobayashi, M. and Tokura, Y. (2008) Possible pathogenic role of Th17 cells for atopic dermatitis. J. Invest. Dermatol. 128, 2625-2630.

Le Poul, E., Loison, C., Berthelot, F., Pinay, C., Aime, J. C., Senéchaud, A., Vivier, V., Vassart, G., van Damme, J., Parmentier, M. and Detheux, M. (2003) Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J. Biol. Chem. 278, 25481-25489.

Lee, J. M., Park, S. J. and Im, D. S. (2017) Calcium signaling of lysophosphatidylethanolamine through LPA1 in human SH-SY5Y neuroblastoma cells. Biomol. Ther. (Seoul) 25, 194-201.

Lee, S. Y., Lee, E., Park, Y. M. and Hong, S. J. (2018) Microbiome in the gut-skin axis in atopic dermatitis. Allergy Asthma Immunol. Res. 10, 354-362.

Lee, T., Schwandner, R., Swaminath, G., Weizsamm, J., Cardozo, M., Greenberg, J., Jaeckel, P., Ge, H., Wang, Y., Jiao, X., Liu, J., Kayser, F., Tian, H. and Li, Y. (2008) Identification and functional characterization of allosteric agonists for the G protein-coupled receptor FFA2. Mol. Pharmacol. 74, 1599-1609.

Leung, D. Y. and Guttmann-Yassky, E. (2017) Assessing the current treatment of atopic dermatitis: unmet needs. J. Allergy Clin. Immunol. 139, S47-S48.

Maslowsk, K. M., Vieira, A. T., Ng, A., Kranich, J., Sierro, F., Yu, D., Schilter, H. C., Rolph, M. S., Mackay, F., Artis, D., Xavier, R. J., Teixeira, M. M. and Mackay, C. R. (2009) Regulation of inflammatory responses by gut microbiota and chemotactant receptor GPR43. Nature 461, 1282-1286.

Miyamoto, J., Kasubuchi, M., Nakajima, A. and Kimura, I. (2017) Anti-inflamatory and insulin-sensitizing effects of free fatty acid receptors. Handb. Exp. Pharmacol. 236, 221-231.

Muraro, A., Lemanske, R. F., Jr., Heiligens, P. W., Akdis, C. A., Bieber, T., Casale, T. B., Jutel, M., Ong, P. Y., Poulsen, L. K., Schmid-Grendelmeier, P., Simon, H. U., Seys, S. F. and Agache, I. (2016) Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J. Allergy Clin. Immunol. 137, 1347-1358.

Nilsson, N. E., Kotarsky, K., Owman, C. and Olde, B. (2003) Identification of a free fatty acid receptor, FFA2R, expressed on leucocytes and activated by short-chain fatty acids. Biochem. Biophys. Res. Commun. 303, 1047-1052.

Park, S. J. and Im, D. S. (2019a) Blockage of sphenosine-1-phosphate receptor 2 attenuates allergic asthma in mice. Br. J. Pharmacol. 176, 938-949.

Park, S. J. and Im, D. S. (2019b) Deficiency of sphenosine-1-phosphate receptor 2 (S1P2) attenuates bleomycin-induced pulmonary fibrosis. Biomol. Ther. (Seoul) 27, 318-326.

Schofield, Z. V., Croker, D., Robertson, A. A. B., Massey, N. L., Donovan, C., Tee, E., Edwards, D., Woodruff, T. M., Halai, R., Hansbro, P. M. and Cooper, M. A. (2018) Characterisation of small molecule ligands 4CMTB and 2CMT as modulators of human FFA2 receptor signalling. Sci. Rep. 8, 17819.

Smith, N. J., Ward, R. J., Stoddart, L. A., Hudson, B. D., Kostenis, E., Ulven, T., Morris, J. C., Trankle, C., Tikhonova, I. G., Adams, D. R. and Milligan, G. (2011) Extracellular loop 2 of the free fatty acid receptor 2 mediates allosterism of a phenylacetamide ago-allosteric modulator. Mol. Pharmacol. 80, 163-173.

Sun, M., Wu, W., Liu, Z. and Cong, Y. (2017) Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases. J. Gastroenterol. 52, 1-8.

Tan, J. K., McKenzie, C., Marino, E., Macia, L. and Mackay, C. R. (2017) Metabolite-sensing G protein-coupled receptors-facilitators of diet-related immune regulation. Annu. Rev. Immunol. 35, 371-402.

Theiler, A., Barnthaler, T., Platzer, W., Richtig, G., Peinhaupt, M., Rittchen, S., Kargl, J., Ulven, T., Marsh, L. M., Marsche, G., Schullgoi, R., Sturm, E. M. and Heinemann, A. (2019) Butyrate ameliorates allergic airway inflammation by limiting eosinophil trafficking and survival. J. Allergy Clin. Immunol. 144, 764-776.

Trompette, A., Gollwitzer, E. S., Yadava, K., Sichelstiel, A. K., Sprenger, N., Ngom-Bru, C., Blanchard, C., Junt, T., Nicod, L. P., Harris, N. L. and Marsland, B. J. (2014) Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat. Med. 20, 159-166.

Ulven, T. (2012) Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets. Front. Endocrinol. (Lausanne) 3, 111.